Payment overview · 2025
General Payments
$158.46
7 reported records · 5 companies
Healthcare provider profile · identity verified
Robert Dekkers, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · SANTA PAULA, CA · NPI 1821083171
Verified facts
What the public records show
CMS Open Payments records show Robert Dekkers, M.D. received $158.46 in general payments during 2025 across 7 reported records.
Novo Nordisk Inc accounted for 47.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $74.77 | 47.2% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $29.50 | 18.6% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $20.67 | 13.0% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $17.29 | 10.9% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $16.23 | 10.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $126.19 | 6 |
| Education | $32.27 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $42.50 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $29.50 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $29.50 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $20.67 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $17.29 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $17.29 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $16.23 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 549 | 135 |
| Levothyroxine Sodium | Levothyroxine Sodium | 459 | 101 |
| Gabapentin | Gabapentin | 343 | 85 |
| Omeprazole | Omeprazole | 300 | 113 |
| Metformin Hcl | Metformin Hcl | 296 | 79 |
| Furosemide | Furosemide | 295 | 106 |
| Eliquis | Apixaban | 262 | 38 |
| Amlodipine Besylate | Amlodipine Besylate | 256 | 66 |
| Losartan Potassium | Losartan Potassium | 247 | 69 |
| Prednisone | Prednisone | 229 | 107 |
| Simvastatin | Simvastatin | 212 | 62 |
| Pantoprazole Sodium | Pantoprazole Sodium | 209 | 69 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 205 | 41 |
| Metoprolol Tartrate | Metoprolol Tartrate | 197 | 44 |
| Januvia | Sitagliptin Phosphate | 170 | 29 |
| Lisinopril | Lisinopril | 168 | 52 |
| Benazepril Hcl | Benazepril Hcl | 147 | 43 |
| Potassium Chloride | Potassium Chloride | 137 | 34 |
| Metoprolol Succinate | Metoprolol Succinate | 127 | 46 |
| Alprazolam | Alprazolam | 120 | 19 |
| Allopurinol | Allopurinol | 119 | 28 |
| Xarelto | Rivaroxaban | 112 | 12 |
| Tamsulosin Hcl | Tamsulosin Hcl | 109 | 43 |
| Sertraline Hcl | Sertraline Hcl | 102 | 36 |
| Carvedilol | Carvedilol | 100 | 29 |
| Azithromycin | Azithromycin | 99 | 75 |
| Clopidogrel | Clopidogrel Bisulfate | 95 | 33 |
| Alendronate Sodium | Alendronate Sodium | 91 | 31 |
| Glipizide | Glipizide | 90 | 30 |
| Levetiracetam | Levetiracetam | 84 | 18 |
| Hydrocortisone | Hydrocortisone | 83 | 34 |
| Atenolol | Atenolol | 81 | 23 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 81 | 64 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 81 | 19 |
| Duloxetine Hcl | Duloxetine Hcl | 77 | 20 |
| Doxazosin Mesylate | Doxazosin Mesylate | 73 | 18 |
| Pregabalin | Pregabalin | 73 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 73 | 22 |
| Warfarin Sodium | Warfarin Sodium | 69 | 15 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 67 | 28 |
| Tramadol Hcl | Tramadol Hcl | 67 | 14 |
| Amitriptyline Hcl | Amitriptyline Hcl | 63 | 17 |
| Bumetanide | Bumetanide | 63 | 22 |
| Fluoxetine Hcl | Fluoxetine Hcl | 63 | 13 |
| Pioglitazone Hcl | Pioglitazone Hcl | 63 | 21 |
| Baclofen | Baclofen | 59 | 11 |
| Divalproex Sodium | Divalproex Sodium | 59 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 56 | 14 |
| Trazodone Hcl | Trazodone Hcl | 55 | 21 |
| Hydrochlorothiazide | Hydrochlorothiazide | 53 | 13 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 52 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 47 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 45 | 14 |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 45 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 42 | 26 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 42 | 12 |
| Lorazepam | Lorazepam | 42 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 42 | 14 |
| Diclofenac Sodium | Diclofenac Sodium | 40 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 40 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 38 | 11 |
| Methenamine Hippurate | Methenamine Hippurate | 38 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 38 | 15 |
| Amiodarone Hcl | Amiodarone Hcl | 37 | 12 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 36 | 28 |
| Jardiance | Empagliflozin | 35 | suppressed |
| Cephalexin | Cephalexin | 34 | 22 |
| Bupropion Xl | Bupropion Hcl | 33 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 32 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 32 | suppressed |
| Xifaxan | Rifaximin | 32 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 31 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 30 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 30 | suppressed |
| Famotidine | Famotidine | 30 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 30 | 14 |
| Bupropion Hcl Sr | Bupropion Hcl | 29 | suppressed |
| Myrbetriq | Mirabegron | 29 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 29 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 28 | suppressed |
| Kristalose | Lactulose | 28 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 28 | suppressed |
| Ibuprofen | Ibuprofen | 27 | suppressed |
| Olanzapine | Olanzapine | 27 | suppressed |
| Valsartan | Valsartan | 27 | suppressed |
| Digoxin | Digoxin | 26 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 25 | suppressed |
| Celecoxib | Celecoxib | 24 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 24 | 11 |
| Premarin | Estrogens, Conjugated | 24 | suppressed |
| Acyclovir | Acyclovir | 23 | suppressed |
| Carisoprodol | Carisoprodol | 23 | suppressed |
| Galantamine Er | Galantamine Hbr | 23 | suppressed |
| Memantine Hcl | Memantine Hcl | 23 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 23 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 23 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 22 | suppressed |
| Mirtazapine | Mirtazapine | 22 | suppressed |
| Novolin R Flexpen | Insulin Regular, Human | 22 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 22 | suppressed |
| Finasteride | Finasteride | 21 | suppressed |
| Fenofibrate | Fenofibrate | 20 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 20 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 19 | suppressed |
| Latanoprost | Latanoprost | 19 | suppressed |
| Lidocaine | Lidocaine | 19 | suppressed |
| Spironolactone | Spironolactone | 19 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 18 | 12 |
| Thiothixene | Thiothixene | 18 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 17 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 16 | suppressed |
| Isosorbide Mononitrate | Isosorbide Mononitrate | 16 | suppressed |
| Levofloxacin | Levofloxacin | 16 | 15 |
| Oxybutynin Chloride | Oxybutynin Chloride | 16 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 16 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 15 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 15 | suppressed |
| Ozempic | Semaglutide | 15 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 15 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 14 | suppressed |
| Ezetimibe | Ezetimibe | 14 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 14 | suppressed |
| Phenobarbital | Phenobarbital | 14 | suppressed |
| Timolol Maleate | Timolol Maleate | 14 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 13 | 12 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 13 | suppressed |
| Folic Acid | Folic Acid | 13 | suppressed |
| Lansoprazole | Lansoprazole | 13 | suppressed |
| Lumigan | Bimatoprost | 13 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Temazepam | Temazepam | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 12 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 12 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 12 | suppressed |
| Sotalol | Sotalol Hcl | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 11 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 11 | suppressed |
| Meloxicam | Meloxicam | 11 | suppressed |
| Methocarbamol | Methocarbamol | 11 | suppressed |
| Mexiletine Hcl | Mexiletine Hcl | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $158.46 · 7 records | Novo Nordisk Inc | Kerendia, MOUNJARO, OTEZLA, Ozempic, REPATHA, SHINGRIX, ZEPBOUND | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error